报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
---|---|---|---|---|---|---|---|---|
2024-09-30 | 69.32% | 14.22% | 2.97% | 32/160 | 22.89% | 迪哲医药 | 97.73% | 行业排名> |
2024-06-30 | 67.32% | 16.9% | 0.08% | 35/160 | 33.26% | 百利天恒 | 97.99% | 行业排名> |
2024-03-31 | 67.26% | 20.25% | 10.32% | 34/160 | 51.37% | 百利天恒 | 98.92% | 行业排名> |
2023-12-31 | 60.97% | 5.9% | 0.46% | 51/160 | 51.38% | 迈威生物 | 98.93% | 行业排名> |
2023-09-30 | 60.69% | 12.87% | 5.39% | 53/160 | 32.75% | 迈威生物 | 99.59% | 行业排名> |
2023-06-30 | 57.59% | 9.31% | 2.95% | 63/160 | 38.61% | 迈威生物 | 99.8% | 行业排名> |
2023-03-31 | 55.93% | 3.15% | -2.85% | 65/160 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
2022-12-31 | 57.57% | 3.26% | 7.08% | 67/160 | 53.57% | 迈威生物 | 99.75% | 行业排名> |
2022-09-30 | 53.77% | -4.72% | 2.06% | 74/160 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
2022-06-30 | 52.68% | -6.37% | -2.85% | 77/160 | 21.79% | 迈威生物 | 99.44% | 行业排名> |
2022-03-31 | 54.23% | -8.51% | -2.75% | 74/160 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
2021-12-31 | 55.76% | -4.14% | -1.19% | 74/160 | 55.07% | 首药控股 | 99.93% | 行业排名> |
2021-09-30 | 56.43% | 3.38% | 0.29% | 63/160 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
2021-06-30 | 56.26% | -2.56% | -5.07% | 69/160 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
2021-03-31 | 59.27% | 7.64% | 1.9% | 55/160 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
2020-12-31 | 58.16% | 8.99% | 0.74% | 64/160 | -143.08% | 首药控股 | 99.94% | 行业排名> |
2020-06-30 | 57.74% | -3.76% | 8.19% | 56/160 | 54.32% | 泽璟制药 | 99.96% | 行业排名> |
2019-12-31 | 53.37% | -11.18% | -2.23% | 71/160 | -1204.25% | 微芯生物 | 95.14% | 行业排名> |
2019-09-30 | 54.58% | -15.69% | -9.02% | 56/160 | 55.47% | 多瑞医药 | 95.59% | 行业排名> |
2019-06-30 | 60% | -8.43% | 8.96% | 50/160 | 55.36% | 微芯生物 | 95.81% | 行业排名> |
2019-03-31 | 55.06% | -17.47% | -8.36% | 55/160 | 51.37% | 微芯生物 | 96.09% | 行业排名> |
2018-12-31 | 60.09% | -2.5% | -7.19% | 53/160 | -205.91% | 微芯生物 | 96.11% | 行业排名> |
2018-09-30 | 64.74% | 2% | -1.19% | 29/160 | 54.25% | 微芯生物 | 95.5% | 行业排名> |
2018-06-30 | 65.52% | 17.71% | -1.8% | 28/160 | 53.68% | 微芯生物 | 96.27% | 行业排名> |
2018-03-31 | 66.72% | 2% | 8.26% | 29/160 | 54.19% | 贝达药业 | 95.47% | 行业排名> |
2017-12-31 | 61.63% | 26.37% | 10.72% | 41/160 | 52.58% | 贝达药业 | 95.51% | 行业排名> |
2017-06-30 | 55.66% | 504.65% | 14.14% | 38/160 | 48.02% | 贝达药业 | 95.54% | 行业排名> |
2016-12-31 | 48.77% | 2% | 429.76% | 53/160 | 48.44% | 贝达药业 | 95.74% | 行业排名> |
2016-06-30 | 9.21% | 2% | 2% | 89/160 | 46.2% | 退市金泰 | 96.19% | 行业排名> |